Commit Biologics Raises $60 million Seed to Take COM002 Into the Clinic and Expand Its Pipeline

Commit Biologics completed a $60 million (€54 million) seed financing round, with the final close led by Ackermans & van Haaren and participation from AbbVie Ventures, M Ventures, Bioqube Ventures, Korys and Novo Holdings. The financing will take COM002 toward the clinic, advance a second program into IND-enabling development and expand its BiCE™ pipeline.
- Raised
- $60 million
- Round
- seed
- Investors
- 6
- Investors
- Ackermans & van HaarenAbbVie VenturesM VenturesBioqube VenturesKorysNovo Holdings
- Target market
- Patients with cancer and autoimmune disease
- Use of funds
- Supporting completion of IND-enabling activities and IND filing for COM002 to take it into the clinic, advancing a second program into IND-enabling development and expanding the BiCE™ pipeline
Get started
Create a free account to read the full story.
Quick Answers
What is the latest news about Commit Biologics?
Commit Biologics completed a $60 million (€54 million) seed financing round, with the final close led by Ackermans & van Haaren and participation from AbbVie Ventures, M Ventures, Bioqube Ventures, Korys and Novo Holdings. The financing will take COM002 toward the clinic, advance a second program into IND-enabling development and expand its BiCE™ pipeline.
What does Commit Biologics do?
Commit Biologics is a biotechnology company developing complement-powered immune engagers. Its BiCE™ approach is designed to direct the complement system against diseased cells, with development focused on cancer and autoimmune disease.
How much did Commit Biologics raise?
Commit Biologics raised $60 million in its seed.
Who invested in Commit Biologics?
Investors named in this seed include Ackermans & van Haaren, AbbVie Ventures, M Ventures, Bioqube Ventures, Korys and Novo Holdings.
How will Commit Biologics use the funding?
Commit Biologics plans to use the money for supporting completion of IND-enabling activities and IND filing for COM002 to take it into the clinic, advancing a second program into IND-enabling development and expanding the BiCE™ pipeline.
Where is Commit Biologics based?
Commit Biologics is based in Denmark.
Who are the key people at Commit Biologics?
Key people named in this report: Dr. Thomas L. F. Montgomery Andresen (CEO) and Mikael B. L. Winkler (Co-founder & Head of Platform Technology).
